Pneumococcal conjugate vaccines target the limited subset of the more than 90 known serotypes of Streptococcus pneumoniae responsible for the greatest burden of pneumococcal disease and antibiotic resistance. Following the introduction of these vaccines, serotypes not targeted were able to expand and resistance became more common within these types. Here we use a stochastic dynamic model of pediatric pneumococcal carriage to evaluate potential influences on the emergence of new resistant lineages following the introduction of a vaccine targeting more common resistant types. Antibiotic pressure was the strongest driver, with no emergence at low levels and universal emergence at high levels. At intermediate levels of antibiotic pressure, high...
Background In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a ca...
BACKGROUND:The long-term effects of selective pressure from conjugate pneumococcal vaccine on the se...
The competitive pressure from non-vaccine serotypes may have helped pneumococcal conjugate vaccines ...
Universal infant vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7) has nearly elim...
The introduction of pneumococcal conjugate vaccines (PCVs) in the early years of the 21st century ha...
The ongoing emergence of antibiotic resistant strains and high frequencies of antibiotic resistance ...
The bacterial pathogen Streptococcus pneumoniae is a major public health concern, being responsible ...
The 7-valent pneumococcal conjugate vaccine has been introduced in national immunisation programmes ...
The competitive pressure from non-vaccine serotypes may have helped pneumococcal conjugate vaccines ...
OBJECTIVE:Despite immunization with heptavalent pneumococcal conjugate vaccine (PCV7), the rising pr...
BackgroundIn response to the selective pressure of pneumococcal conjugate vaccine, increased asympto...
BACKGROUND: There are more than 90 serotypes of Streptococcus pneumoniae, with varying biologic and ...
INTRODUCTION: Pneumococcal multiple serotype carriage is important for evolution of the species and ...
Streptococcus pneumoniae causes substantial mortality among children under 5-years-old worldwide. Po...
International audienceAntibiotic-use policies may affect pneumococcal conjugate-vaccine effectivenes...
Background In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a ca...
BACKGROUND:The long-term effects of selective pressure from conjugate pneumococcal vaccine on the se...
The competitive pressure from non-vaccine serotypes may have helped pneumococcal conjugate vaccines ...
Universal infant vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7) has nearly elim...
The introduction of pneumococcal conjugate vaccines (PCVs) in the early years of the 21st century ha...
The ongoing emergence of antibiotic resistant strains and high frequencies of antibiotic resistance ...
The bacterial pathogen Streptococcus pneumoniae is a major public health concern, being responsible ...
The 7-valent pneumococcal conjugate vaccine has been introduced in national immunisation programmes ...
The competitive pressure from non-vaccine serotypes may have helped pneumococcal conjugate vaccines ...
OBJECTIVE:Despite immunization with heptavalent pneumococcal conjugate vaccine (PCV7), the rising pr...
BackgroundIn response to the selective pressure of pneumococcal conjugate vaccine, increased asympto...
BACKGROUND: There are more than 90 serotypes of Streptococcus pneumoniae, with varying biologic and ...
INTRODUCTION: Pneumococcal multiple serotype carriage is important for evolution of the species and ...
Streptococcus pneumoniae causes substantial mortality among children under 5-years-old worldwide. Po...
International audienceAntibiotic-use policies may affect pneumococcal conjugate-vaccine effectivenes...
Background In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a ca...
BACKGROUND:The long-term effects of selective pressure from conjugate pneumococcal vaccine on the se...
The competitive pressure from non-vaccine serotypes may have helped pneumococcal conjugate vaccines ...